Skip to main content

J&J: Sole Defendant In The Oklahoma State Opioid Trial

J&J: Sole Defendant In The Oklahoma State Opioid Trial

J&J: Sole Defendant In The Oklahoma State Opioid Trial

Introduction

Oklahoma State Attorney General Mike Hunter made an announcement on May 26, Sunday, stating that Teva Pharmaceuticals made a settlement of $85 million over alleged link to the opioid epidemic, two days before the trial.

Following the settlement, J&J and its subsidiary Janssen Pharmaceuticals Inc. are the only remaining defendants in the litigation. The trial is considered to be one of the state's first in testing drugmaker liability for an epidemic of painkiller abuse. The state is seeking at least $10 billion in damages and penalties for the opioid epidemic. Around 42 states and more than 1,900 municipalities have sued the companies, demanding billions of dollars in damages.

In a similar trial held in March, OxyContin maker Purdue Pharma LP made a settlement of $270 million. U.S. District Judge Dan Polster is presiding over more than 1,900 suits filed by U.S. cities and counties of which more than 1,600 cases are filed largely by local governments, Native American tribes, and hospitals. The first trial in the MDL No. 2804 is set to start in October 2019.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.